Post-earnings recap
Reported
Mon, Aug 8, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Castle Biosciences reported a narrower-than-expected loss per share, which is a positive surprise for investors. However, the stock fell by 6.81%, indicating that investors may have had higher expectations or concerns about other aspects of the company's performance. The lack of revenue data and management commentary may have contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.06 | N/A | +89.57% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.